CSL has lobbed a US$11.7bn all cash public tender offer for Switzerland based specialty drug company Vifor Pharma.
The acquisition is being funded via a combination of a private placement, SPP and cash/debt, with commencement around 18 Jan-22.


CSL has lobbed a US$11.7bn all cash public tender offer for Switzerland based specialty drug company Vifor Pharma.
The acquisition is being funded via a combination of a private placement, SPP and cash/debt, with commencement around 18 Jan-22.

Join Investor Signals today and start your journey to better, more disciplined returns.